Keros Therapeutics (KROS) Preferred Stock Liabilities (2019 - 2020)
Keros Therapeutics posted quarterly Preferred Stock Liabilities of $55.8 million for Q1 2020, up 512.57% year-on-year from $9.1 million in Q2 2019, and up 179.73% on a QoQ basis from $19.9 million in Q4 2019.
Keros Therapeutics (KROS) has 2 years of Preferred Stock Liabilities data on file, last reported at $55.8 million in Q1 2020.
- For the quarter ending Q1 2020, Preferred Stock Liabilities rose 512.57% year-over-year to $55.8 million; the trailing twelve-month figure through Mar 2020 stood at $55.8 million (up 512.57% YoY), and the FY2019 full-year result was $19.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q1 2020 stood at $55.8 million, up from $19.9 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $55.8 million in Q1 2020 and bottomed at $9.1 million in Q1 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 55.78 Mn |
| Dec 31, 2019 | 19.94 Mn |
| Sep 30, 2019 | 9.89 Mn |
| Jun 30, 2019 | 9.11 Mn |
| Mar 31, 2019 | 9.11 Mn |